|
|
|
Insider
Information: |
Squinto Stephen P |
Relationship: |
Director, 10% Owner |
City: |
Cheshire |
State: |
CT |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
2 |
|
Direct
Shares |
238,160 |
|
Indirect Shares
|
6,290,493 |
|
|
Direct
Value |
$19,437,710 |
|
|
Indirect Value
|
$19,013,945 |
|
|
Total
Shares |
6,528,653 |
|
|
Total
Value |
$38,451,655 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Alexion Pharmaceuticals Inc |
ALXN |
EVP, Chief Global Ops.... |
2014-10-27 |
106,508 |
2013-10-28 |
104,186 |
Premium* |
|
Springworks Therapeutics, Inc. |
SWTX |
Director, 10% Owner |
2022-05-19 |
131,652 |
2022-05-19 |
6,186,307 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
148 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 4 of 6
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
|
2011-03-02 |
4 |
OE |
$20.58 |
$102,900 |
D/D |
5,000 |
44,637 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Global Ops. Officer |
|
2014-10-27 |
4 |
OE |
$42.66 |
$348,140 |
D/D |
5,550 |
112,418 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Global Ops. Officer |
|
2014-10-27 |
4 |
AS |
$188.36 |
$1,114,532 |
D/D |
(5,910) |
106,508 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Research and Development |
|
2011-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
7,000 |
39,917 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
|
2006-11-13 |
4 |
AS |
$42.76 |
$342,175 |
D/D |
(8,000) |
12,272 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
|
2006-11-13 |
4 |
OE |
$10.50 |
$84,000 |
D/D |
8,000 |
20,272 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
|
2009-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
33,590 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of R&D |
|
2010-01-28 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
35,454 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
|
2007-04-03 |
4 |
OE |
$10.50 |
$99,750 |
D/D |
9,500 |
25,014 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
|
2007-04-03 |
4 |
AS |
$43.52 |
$413,673 |
D/D |
(9,500) |
15,514 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Global Ops. Officer |
|
2014-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
9,745 |
104,563 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
Executive VP& Head of Research |
|
2004-08-16 |
4 |
S |
$15.30 |
$153,000 |
D/D |
(10,000) |
15,476 |
|
- |
|
ALXN |
Alexion Pharmaceuticals I... |
Exec VP & Head of Research |
|
2004-09-15 |
4 |
AS |
$17.50 |
$176,250 |
D/D |
(10,000) |
23,601 |
|
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of R&D |
|
2010-11-03 |
4 |
S |
$70.14 |
$701,400 |
D/D |
(10,000) |
34,873 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of R&D |
|
2010-11-03 |
4 |
OE |
$10.36 |
$103,600 |
D/D |
10,000 |
44,873 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Research and Development |
|
2011-02-18 |
4 |
S |
$94.42 |
$944,200 |
D/D |
(10,000) |
39,637 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Research and Development |
|
2011-02-18 |
4 |
OE |
$20.58 |
$205,800 |
D/D |
10,000 |
49,637 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Global Ops. Officer |
|
2014-10-03 |
4 |
OE |
$42.66 |
$427,666 |
D/D |
10,025 |
116,893 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Global Ops. Officer |
|
2014-10-03 |
4 |
AS |
$169.95 |
$1,728,374 |
D/D |
(10,025) |
106,868 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of R&D |
|
2010-09-13 |
4 |
S |
$60.89 |
$756,010 |
D/D |
(12,416) |
34,873 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of R&D |
|
2010-09-13 |
4 |
OE |
$10.19 |
$137,346 |
D/D |
12,416 |
39,873 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Head of Research |
|
2004-11-17 |
4 |
AS |
$20.58 |
$272,410 |
D/D |
(13,125) |
28,126 |
|
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Head of Research |
|
2004-11-17 |
4 |
OE |
$2.38 |
$31,172 |
D/D |
13,125 |
41,251 |
|
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Global Ops. Officer |
|
2013-08-02 |
4 |
OE |
$22.90 |
$446,963 |
D/D |
14,125 |
121,467 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Global Ops. Officer |
|
2013-08-02 |
4 |
AS |
$114.95 |
$1,629,018 |
D/D |
(14,125) |
107,342 |
0 |
- |
|
148 Records found
|
|
Page 4 of 6 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|